<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38172498</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>01</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month><Day>03</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Efficacy of an eHealth self-management program in reducing irritable bowel syndrome symptom severity: a randomized controlled trial.</ArticleTitle><Pagination><StartPage>4</StartPage><MedlinePgn>4</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-50293-z</ELocationID><Abstract><AbstractText>This study aimed to verify whether an eHealth-based self-management program can reduce irritable bowel syndrome (IBS) symptom severity. An open-label simple randomized controlled trial was conducted that compared an intervention group (n&#x2009;=&#x2009;21) participating in an eHealth self-management program, which involved studying IBS-related information from an established self-help guide followed by in-built quizzes, with a treatment-as-usual group (n&#x2009;=&#x2009;19) that, except for pharmacotherapy, had no treatment restrictions. Participants were female Japanese university students. The eHealth group received unlimited access to the self-management program for 8&#xa0;weeks on computers and mobile devices. The primary outcome, participants' severity of IBS symptoms assessed using the IBS-severity index (IBS-SI), and the secondary outcomes of participants' quality of life, gut bacteria, and electroencephalography alpha and beta power percentages were measured at baseline and 8&#xa0;weeks. A significant difference was found in the net change in IBS-SI scores between the eHealth and treatment-as-usual groups, and the former had significantly lower IBS-SI scores following the 8-week intervention than at baseline. Moreover, there was a significant difference in the net change in phylum Cyanobacteria between the eHealth and treatment-as-usual groups. Thus, the eHealth-based self-management program successfully reduced the severity of IBS symptoms.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Tayama</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Faculty of Human Sciences, Waseda University, 2-579-15 Mikajima, Tokorozawa, Saitama, 359-1192, Japan. jtayama@waseda.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Hamaguchi</LastName><ForeName>Toyohiro</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Occupational Therapy, School of Health and Social Services, Saitama Prefectural University, 820, Sannomiya, Koshigaya, Saitama, 343-8540, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koizumi</LastName><ForeName>Kohei</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Occupational Therapy, School of Health and Social Services, Saitama Prefectural University, 820, Sannomiya, Koshigaya, Saitama, 343-8540, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamura</LastName><ForeName>Ryodai</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Biomedical Oncology, Institute for Genetic Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, Hokkaido, 060-0815, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okubo</LastName><ForeName>Ryo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Neurology, National Hospital Organization Obihiro Hospital, 16, Kita 2, Nishi 18, Obihiro, Hokkaido, 080-0048, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawahara</LastName><ForeName>Jun-Ichiro</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Department of Psychology, Hokkaido University, Kita 10, Nishi 7, Kita-Ku, Sapporo, Hokkaido, 060-0815, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Kenji</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Student Success Research and Practice, Osaka University, 1-2, Yamadaoka, Suita, Osaka, 565-0871, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeoka</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Health Center, Nagasaki University, 1-14, Bunkyo, Nagasaki, Nagasaki, 852-8521, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukudo</LastName><ForeName>Shin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, 2-1, Seiryo-Machi, Aoba-ku, Sendai, Miyagi, 980-8575, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>18KK0275</GrantID><Agency>the Japan Society for the Promotion of Science for the Fostering Joint International Research (B)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073278" MajorTopicYN="Y">Self-Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017216" MajorTopicYN="Y">Telemedicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>4</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>3</Day><Hour>23</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38172498</ArticleId><ArticleId IdType="pmc">PMC10764726</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-50293-z</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-50293-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396:1675&#x2013;1688. doi: 10.1016/S0140-6736(20)31548-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31548-8</ArticleId><ArticleId IdType="pubmed">33049223</ArticleId></ArticleIdList></Reference><Reference><Citation>Elsenbruch S. Abdominal pain in irritable bowel syndrome: a review of putative psychological, neural and neuro-immune mechanisms. Brain Behav Immun. 2011;25:386&#x2013;394. doi: 10.1016/j.bbi.2010.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.11.010</ArticleId><ArticleId IdType="pubmed">21094682</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber AD, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: A Rome Foundation working team literature review. Gut. 2017;66:1075&#x2013;1082. doi: 10.1136/gutjnl-2015-311240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311240</ArticleId><ArticleId IdType="pubmed">26818616</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanazawa M, et al. Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J) Biopsychosoc. Med. 2007;1:6. doi: 10.1186/1751-0759-1-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1751-0759-1-6</ArticleId><ArticleId IdType="pmc">PMC1832201</ArticleId><ArticleId IdType="pubmed">17371576</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxion-Bergemann S, Thielecke F, Abel F, Bergemann R. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics. 2006;24:21&#x2013;37. doi: 10.2165/00019053-200624010-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00019053-200624010-00002</ArticleId><ArticleId IdType="pubmed">16445300</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy, B. E. <i>et al.</i> ACG clinical guideline: management of irritable bowel syndrome. <i>Am. J. Gastroenterol.</i><b>116,</b> 17&#x2013;44. 10.14309/ajg.0000000000001036 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33315591</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukudo S, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J. Gastroenterol. 2021;56:193&#x2013;217. doi: 10.1007/s00535-020-01746-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-020-01746-z</ArticleId><ArticleId IdType="pmc">PMC7932982</ArticleId><ArticleId IdType="pubmed">33538894</ArticleId></ArticleIdList></Reference><Reference><Citation>Wouters MM, et al. Altered brain activation to colorectal distention in visceral hypersensitive maternal-separated rats. Neurogastroenterol Motil. 2012;24:678&#x2013;685. doi: 10.1111/j.1365-2982.2012.01919.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2012.01919.x</ArticleId><ArticleId IdType="pubmed">22509925</ArticleId></ArticleIdList></Reference><Reference><Citation>Lackner JM, et al. Improvement in gastrointestinal symptoms after cognitive behavior therapy for refractory irritable bowel syndrome. Gastroenterology. 2018;155:47&#x2013;57. doi: 10.1053/j.gastro.2018.03.063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2018.03.063</ArticleId><ArticleId IdType="pmc">PMC6035059</ArticleId><ArticleId IdType="pubmed">29702118</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamaguchi T, et al. The effects of locomotor activity on gastrointestinal symptoms of irritable bowel syndrome among younger people: an observational study. PLOS ONE. 2020;15:e0234089. doi: 10.1371/journal.pone.0234089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0234089</ArticleId><ArticleId IdType="pmc">PMC7259724</ArticleId><ArticleId IdType="pubmed">32470098</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntosh K, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: A randomised controlled trial. Gut. 2017;66:1241&#x2013;1251. doi: 10.1136/gutjnl-2015-311339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311339</ArticleId><ArticleId IdType="pubmed">26976734</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice KL, et al. Disease management program for chronic obstructive pulmonary disease: A randomized controlled trial. Am. J. Respir. Crit. Care Med. 2010;182:890&#x2013;896. doi: 10.1164/rccm.200910-1579OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200910-1579OC</ArticleId><ArticleId IdType="pubmed">20075385</ArticleId></ArticleIdList></Reference><Reference><Citation>Cameron-Tucker HL, Wood-Baker R, Owen C, Joseph L, Walters EH. Chronic disease self-management and exercise in COPD as pulmonary rehabilitation: A randomized controlled trial. Int. J. Chron. Obstruct. Pulmon. Dis. 2014;9:513&#x2013;523. doi: 10.2147/COPD.S58478.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/COPD.S58478</ArticleId><ArticleId IdType="pmc">PMC4037329</ArticleId><ArticleId IdType="pubmed">24876771</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson A, et al. A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome. Gut. 2006;55:643&#x2013;648. doi: 10.1136/gut.2004.062901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2004.062901</ArticleId><ArticleId IdType="pmc">PMC1856107</ArticleId><ArticleId IdType="pubmed">16099784</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy A, Robinson A, Rogers A. Incorporating patients' views and experiences of life with IBS in the development of an evidence based self-help guidebook. Patient Educ. Couns. 2003;50:303&#x2013;310. doi: 10.1016/s0738-3991(03)00054-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0738-3991(03)00054-5</ArticleId><ArticleId IdType="pubmed">12900104</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider A, et al. Self-help guidebook improved quality of life for patients with irritable bowel syndrome. PLOS ONE. 2017;12:e0181764. doi: 10.1371/journal.pone.0181764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0181764</ArticleId><ArticleId IdType="pmc">PMC5526555</ArticleId><ArticleId IdType="pubmed">28742808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy A, Robinson JA, Thompson DG, Wilkin D. Development of a guidebook to promote patient participation in the management of ulcerative colitis. Health Soc. Care Community. 1999;7:177&#x2013;186. doi: 10.1046/j.1365-2524.1999.00174.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2524.1999.00174.x</ArticleId><ArticleId IdType="pubmed">11560632</ArticleId></ArticleIdList></Reference><Reference><Citation>Ankersen DV, et al. Long-term effects of a web-based low-FODMAP diet versus probiotic treatment for irritable bowel syndrome, including shotgun analyses of microbiota: Randomized, double-crossover clinical trial. J. Med. Internet Res. 2021;23:e30291. doi: 10.2196/30291.</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/30291</ArticleId><ArticleId IdType="pmc">PMC8715363</ArticleId><ArticleId IdType="pubmed">34904950</ArticleId></ArticleIdList></Reference><Reference><Citation>Pedersen N, et al. Ehealth: Low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World J. Gastroenterol. 2014;20:16215&#x2013;16226. doi: 10.3748/wjg.v20.i43.16215.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i43.16215</ArticleId><ArticleId IdType="pmc">PMC4239510</ArticleId><ArticleId IdType="pubmed">25473176</ArticleId></ArticleIdList></Reference><Reference><Citation>Hori M, et al. A suitable m-learning system using e-book for developing countries. CSEDU. 2016;2:408&#x2013;415. doi: 10.5220/0005880104080415.</Citation><ArticleIdList><ArticleId IdType="doi">10.5220/0005880104080415</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinozaki M, et al. Validation of the Japanese version of the Rome II modular questionnaire and irritable bowel syndrome severity index. J. Gastroenterol. 2006;41:491&#x2013;494. doi: 10.1007/s00535-006-1799-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-006-1799-9</ArticleId><ArticleId IdType="pubmed">16799892</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: A simple method of monitoring irritable bowel syndrome and its progress. Aliment. Pharmacol. Ther. 1997;11:395&#x2013;402. doi: 10.1046/j.1365-2036.1997.142318000.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.1997.142318000.x</ArticleId><ArticleId IdType="pubmed">9146781</ArticleId></ArticleIdList></Reference><Reference><Citation>Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: Development and validation of a new measure. Dig. Dis. Sci. 1998;43:400&#x2013;411. doi: 10.1023/a:1018831127942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/a:1018831127942</ArticleId><ArticleId IdType="pubmed">9512138</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukudo S, Nomura T, Muranaka M, Taguchi F. Brain-gut response to stress and cholinergic stimulation in irritable bowel syndrome: A preliminary study. J. Clin. Gastroenterol. 1993;17:133&#x2013;141. doi: 10.1097/00004836-199309000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004836-199309000-00009</ArticleId><ArticleId IdType="pubmed">8031340</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittayanon R, et al. Gut microbiota in patients with irritable bowel syndrome-a systematic review. Gastroenterology. 2019;157:97&#x2013;108. doi: 10.1053/j.gastro.2019.03.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.03.049</ArticleId><ArticleId IdType="pubmed">30940523</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson CA, Mu A, Haslam N, Schwartz OS, Simmons JG. Feeling down? A systematic review of the gut microbiota in anxiety/depression and irritable bowel syndrome. J. Affect. Disord. 2020;266:429&#x2013;446. doi: 10.1016/j.jad.2020.01.124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2020.01.124</ArticleId><ArticleId IdType="pubmed">32056910</ArticleId></ArticleIdList></Reference><Reference><Citation>Jasper HH. The 10&#x2013;20 electrode system of the international federation. Electroencephalogr. Clin. Neurophysiol. 1958;10:371&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">10590970</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolyen E. producible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat. Biotechnol. 2019;37:852&#x2013;857. doi: 10.1038/s41587-019-0209-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0209-9</ArticleId><ArticleId IdType="pmc">PMC7015180</ArticleId><ArticleId IdType="pubmed">31341288</ArticleId></ArticleIdList></Reference><Reference><Citation>Segata N, et al. Metagenomic biomarker discovery and explanation. Genome Biol. 2011;12:R60. doi: 10.1186/gb-2011-12-6-r60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2011-12-6-r60</ArticleId><ArticleId IdType="pmc">PMC3218848</ArticleId><ArticleId IdType="pubmed">21702898</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanchard EB, Greene B, Scharff L, Schwarz-McMorris SP. Relaxation training as a treatment for irritable bowel syndrome. Biofeedback Self Regul. 1993;18:125&#x2013;132. doi: 10.1007/BF00999789.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00999789</ArticleId><ArticleId IdType="pubmed">8218507</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto LS, et al. Health effects of exposure to cyanobacteria (blue-green algae) during recreational water-related activities. Aust. N. Z. J. Public Health. 1997;21:562&#x2013;566. doi: 10.1111/j.1467-842X.1997.tb01755.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1467-842X.1997.tb01755.x</ArticleId><ArticleId IdType="pubmed">9470258</ArticleId></ArticleIdList></Reference><Reference><Citation>Lad, A. <i>et al.</i> As we drink and breathe: Adverse health effects of microcystins and other harmful algal bloom toxins in the liver, gut, lungs and beyond. <i>Life (Basel)</i>. <b>12,</b> 418. 10.3390/life12030418 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8950847</ArticleId><ArticleId IdType="pubmed">35330169</ArticleId></ArticleIdList></Reference><Reference><Citation>Chumpitazi BP, et al. Fructan-sensitive children with irritable bowel syndrome have distinct gut microbiome signatures. Aliment. Pharmacol. Ther. 2021;53:499&#x2013;509. doi: 10.1111/apt.16204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.16204</ArticleId><ArticleId IdType="pmc">PMC8281336</ArticleId><ArticleId IdType="pubmed">33314183</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, et al. Synergistic effect of berberine-based Chinese medicine assembled nanostructures on diarrhea-predominant irritable bowel syndrome in vivo. Front. Pharmacol. 2020;11:1210. doi: 10.3389/fphar.2020.01210.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.01210</ArticleId><ArticleId IdType="pmc">PMC7490548</ArticleId><ArticleId IdType="pubmed">32982718</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogawa U, et al. Gut microbiota depletion by chronic antibiotic treatment alters the sleep/wake architecture and sleep EEG power spectra in mice. Sci. Rep. 2020;10:19554. doi: 10.1038/s41598-020-76562-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-76562-9</ArticleId><ArticleId IdType="pmc">PMC7659342</ArticleId><ArticleId IdType="pubmed">33177599</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen AP, et al. Bifidobacterium longum 1714 as a translational psychobiotic: Modulation of stress, electrophysiology and neurocognition in healthy volunteers. Transl. Psychiatry. 2016;6:e939. doi: 10.1038/tp.2016.191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/tp.2016.191</ArticleId><ArticleId IdType="pmc">PMC5314114</ArticleId><ArticleId IdType="pubmed">27801892</ArticleId></ArticleIdList></Reference><Reference><Citation>Tayama J, Sagami Y, Shimada Y, Hongo M, Fukudo S. Effect of alpha-helical CRH on quantitative electroencephalogram in patients with irritable bowel syndrome. Neurogastroenterol. Motil. 2007;19:471&#x2013;483. doi: 10.1111/j.1365-2982.2007.00903.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2007.00903.x</ArticleId><ArticleId IdType="pubmed">17564629</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagami Y, et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut. 2004;53:958&#x2013;964. doi: 10.1136/gut.2003.018911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2003.018911</ArticleId><ArticleId IdType="pmc">PMC1774093</ArticleId><ArticleId IdType="pubmed">15194643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SK, et al. The association between irritable bowel syndrome and the coexistence of depression and insomnia. J. Psychosom. Res. 2017;93:1&#x2013;5. doi: 10.1016/j.jpsychores.2016.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpsychores.2016.12.007</ArticleId><ArticleId IdType="pubmed">28107884</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>